biostudies-arrayexpressUnknownTranscriptomicsGenomicsProteomicsClaire DunicanZymo ResearchIllumina NovaSeq 6000PAXgene tubesQiagenRNA-seq of total RNAHomo sapiensHomo sapienshttps://www.ebi.ac.uk/biostudies/studies/E-MTAB-14728For our RNA velocity study we used whole-blood RNA-Seq data generated from a 399 subset (patients with suspected infection) of the Personalized Risk assessment in Febrile illness to Optimize Real-life Management across the European Union (PERFORM) study cohort - a multi-country prospective observational study of children with suspected infection presenting to hospitals in Europe. We also included 19 non-infection control subjects recruited to PERFORM, predominantly from out-patient settings, who were well at the time of attendance and the reason for attendance was unlikely to affect the blood transcriptome, for example pre-surgical assessment for polydactyly or tonsillectomy. Total RNA was isolated using PAXgene miRNA blood extraction kits (Qiagen), and after additional DNAse treatment (Zymo Research), was sent for ribodepletion library preparation and RNA-Seq at The Wellcome Centre for Human Genetics in Oxford, United Kingdom, using a Novaseq6000 platform at 150bp paired-end configuration, generating a raw read count of ~30 million reads per sample. Samples are from paired end data (_1 and _2). Clinical events of the same person have the same number (PERFORM_number). The event number is specified under the E part of the sample name. Timepoint is specified by TP. All samples in this submission are timepoint 1.biostudies-arrayexpressSequencing - The Novaseq6000 platform at 150bp paired-end configuration generated a raw read count of ~30 million reads per sample. This was performed at The Wellcome Centre for Human Genetics in Oxford, United Kingdom.Sample Collection - Blood was collected for research purposes at the same time as the first clinically indicated samples (wherever possible), and otherwise within 48 hours of admission. 2.5ml whole blood was collected for RNA expression analysis in PAXgene tubes (for children below 1 year of age, 1ml blood was collected into appropriately reduced volumes of PAXgene fluid) and frozen for later analysis.Nucleic Acid Extraction - Total RNA was isolated using PAXgene miRNA blood extraction kits (Qiagen), and then sent for additional DNAse treatment (Zymo Research).Library Construction - Ribodepletion library preparation and RNA-Seq was performed at The Wellcome Centre for Human Genetics in Oxford, United Kingdom.OrganizationMINSEQE ScoreAssays and DataMAGE-TAB FilesClaire DunicanfalseRNA velocity analysis of the PERFORM RNA-Seq datasetFor our RNA velocity study we used whole-blood RNA-Seq data generated from a 399 subset (patients with suspected infection) of the Personalized Risk assessment in Febrile illness to Optimize Real-life Management across the European Union (PERFORM) study cohort - a multi-country prospective observational study of children with suspected infection presenting to hospitals in Europe. We also included 19 non-infection control subjects recruited to PERFORM, predominantly from out-patient settings, who were well at the time of attendance and the reason for attendance was unlikely to affect the blood transcriptome, for example pre-surgical assessment for polydactyly or tonsillectomy. Total RNA was isolated using PAXgene miRNA blood extraction kits (Qiagen), and after additional DNAse treatment (Zymo Research), was sent for ribodepletion library preparation and RNA-Seq at The Wellcome Centre for Human Genetics in Oxford, United Kingdom, using a Novaseq6000 platform at 150bp paired-end configuration, generating a raw read count of ~30 million reads per sample. Samples are from paired end data (_1 and _2). Clinical events of the same person have the same number (PERFORM_number). The event number is specified under the E part of the sample name. Timepoint is specified by TP. All samples in this submission are timepoint 1.2026-02-10T00:00:00Z2026-02-10T09:26:21.904Z2024-12-24T16:58:29.918ZE-MTAB-14728ERP167412EFO_0002944EFO_0004170EFO_0009653EFO_0005518EFO_0004184